GlassScriptPhysician profile
Franco Song Seo
NPI 1609027788
$4,450.99
in general payments reported to CMS, 2019-2025
25 companies · $553 in 2025
The $553 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,158 · 2020: $695 · 2021: $99.48 · 2022: $43.55 · 2023: $57.87 · 2024: $843 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,454.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $853.00 | 2019-2022 | |
| Neuronetics, INC. | $502.20 | 2021-2024 | Neurostar Tms Therapy System |
| Lundbeck LLC | $454.59 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $392.17 | 2019-2025 | Trintellix |
| Alkermes, INC. | $339.52 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $310.60 | 2019-2024 | Abilify Maintena, Rexulti |
| Allergan, INC. | $233.23 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $225.53 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $176.96 | 2024-2025 | Cobenfy |
| Indivior INC. | $174.91 | 2019-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $169.62 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.14 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $68.75 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $62.33 | 2020-2025 | Fanapt |
| Eisai INC. | $50.91 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $49.15 | 2019 | |
| Shire North American Group INC | $43.29 | 2019 | |
| Supernus Pharmaceuticals, INC. | $42.79 | 2021-2025 | Qelbree |
| Upsher-Smith Laboratories LLC | $39.96 | 2019 | |
| Ironshore Pharmaceuticals INC. | $38.31 | 2019-2023 | Jornay Pm |
| Sage Therapeutics, LLC | $26.01 | 2025 | Zurzuvae |
| Noven Therapeutics, LLC | $24.08 | 2025 | Secuado |
| Avanir Pharmaceuticals, INC. | $20.08 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.64 | 2019 | |
| Abbvie INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franco Song Seo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.